Actively Recruiting
Phase 2b Randomized Study Evaluating CBL-514 Injection Compared to Placebo for Reducing Abdominal Subcutaneous Fat with Long-term Re-Treatment
Led by Caliway Biopharmaceuticals Co., Ltd. · Updated on 2026-10-20
250
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with significant abdominal fat to evaluate the effects of CBL-514 injection in reducing subcutaneous fat. This phase 2b randomized, placebo-controlled study aims to assess the efficacy, safety, and tolerability of multiple injections of CBL-514, compared to a saline placebo, with long-term re-treatment. The study focuses on adults with Grade 3 or Grade 4 abdominal fat as determined by both clinician and participant assessments. Participants will receive up to four subcutaneous treatments of either CBL-514 injection or a placebo solution, administered to the abdomen every three weeks. Each treatment consists of up to 120 mL of the assigned study drug. The trial uses a parallel design with random assignment to either the CBL-514 group or the placebo group to compare outcomes. Throughout the study, participants will undergo assessments to measure changes in abdominal fat at baseline and after treatment, including evaluations at 4 and 12 weeks following the final treatment. These assessments include clinician and patient-reported abdominal fat rating scales. Safety and tolerability will be monitored, with participants expected to follow study procedures and maintain a stable lifestyle. The total study duration spans from screening through final follow-up, ending in November 2027.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Research Team
J
Joanna Lu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here